European regulators have started publishing the full clinical trial reports for drugs that are approved for use in the European Union. Results can be accessed at https://clinicaldata.ema.europa.eu/web/cdp/home.

As Nature Reviews Drug Discovery went to press, the agency had released data for only two drugs: Onyx Pharmaceuticals' carfilzomib and AstraZeneca's lesinurad. The combined reports for these two drugs alone are 260,000 pages long. The European Medicines Agency (EMA) plans to publish clinical data on 2–4 products per month. Once it has cleared a backlog of publishable reports, it will release data for new drugs within 60 days of approval decisions. It will also release data for drugs that are withdrawn before a decision is made.

“Patients and clinicians have been waiting a long time for clinical trial data,” said Yann Le Cam, Chief Executive Officer of EURORDIS – Rare Diseases Europe and member of the EMA's management board. “Access to this new knowledge base can help to accelerate innovation by reducing duplication of research and de-risking some new developments.”